The National Institutes of Health has awarded AxioMx a Small Business Innovation Research (SBIR) grant to fund the development of multiplex antigen screening technology. The technology allows the discovery of antibodies against thousands of protein/peptide targets in a single experiment.

“Researchers could capitalize on the power of this technology in a number of intriguing ways from generating antibodies against the entire proteome of an emerging pathogenic organism to screening sets of overlapping peptides encompassing one or several large proteins,” Michael Weiner, chief scientific officer and founder of AxioMx, said.